James C. Shehan, Chair of Lowenstein’s FDA Regulatory practice, comments in several media outlets on the U.S. Food & Drug Administration’s controversial, landmark approval of a new drug for patients with Alzheimer’s. In Reuters and National Post, he observes: “The agency has gotten comfortable with the accelerated approval pathway." In Law360, Shehan adds: "It has all the ingredients of a good FDA story.”